Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center Journal Article


Authors: Geller, S.; Lebowitz, E.; Pulitzer, M. P.; Horwitz, S. M.; Moskowitz, A. J.; Dusza, S.; Myskowski, P. L.
Article Title: Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center
Abstract: Background: The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients. Objective: To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS. Methods: Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018. Results: We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P =.002) and progression-free survival (P =.014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. Limitations: A retrospective study at a single cancer center. Conclusion: MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions. © 2019 American Academy of Dermatology, Inc.
Keywords: adolescent; adult; child; treatment outcome; aged; survival analysis; major clinical study; overall survival; clinical feature; advanced cancer; cancer growth; methotrexate; cancer staging; outcome assessment; follow up; antineoplastic agent; progression free survival; skin defect; steroid; retrospective study; cancer mortality; chlormethine; cancer center; erythema; hyperpigmentation; lactate dehydrogenase; cancer classification; racial disparity; race difference; romidepsin; lactate dehydrogenase blood level; mycosis fungoides; african american; hypopigmentation; sezary syndrome; bexarotene; cutaneous lymphoma; cancer prognosis; human; male; female; priority journal; article; black person; mf; hyperpigmented mf; hypopigmented mf; skin of color
Journal Title: Journal of the American Academy of Dermatology
Volume: 83
Issue: 2
ISSN: 0190-9622
Publisher: Mosby Elsevier  
Date Published: 2020-08-01
Start Page: 430
End Page: 439
Language: English
DOI: 10.1016/j.jaad.2019.08.073
PUBMED: 31499157
PROVIDER: scopus
PMCID: PMC7058509
DOI/URL:
Notes: Article -- Export Date: 1 September 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Melissa P Pulitzer
    205 Pulitzer
  2. Stephen Dusza
    290 Dusza
  3. Steven M Horwitz
    664 Horwitz
  4. Alison Moskowitz
    355 Moskowitz
  5. Patricia Myskowski
    218 Myskowski
  6. Shamir Geller
    55 Geller